Dr Jorge Cortes speaks to ecancer about efficacy and safety results of the phase 2 ASC2ESCALATE trial.

The study evaluated asciminib (ASC) in patients with chronic myeloid leukaemia in chronic phase (CML-CP) after 1 prior TKI (2L).

Dr Cortes says that at week 48, ASC demonstrated high molecular response rates and reached major molecular response (MMR). Responses were especially strong in patients who discontinued prior therapy due to intolerance.

He concludes by highlighting that these findings support ASC as a promising treatment option in the 2L CML-CP setting, with ongoing evaluation of dose escalation strategies for patients not meeting response milestones.